Advertisement

Organisation › Details
ADC Therapeutics S.A. (NYSE: ADCT)
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. *
![]() |
Start | 2012-03-26 established pred |
Group | ADC Therapeutics (Group) | |
Predecessor | ADC Therapeutics S.à.r.l. (ADCT) | |
![]() |
Industry | antibody-drug conjugates (ADC) technology |
Industry 2 | cancer drug | |
![]() |
Person | Mallik, Ameet (ADC Therapeutics 202205– CEO before Rafael Holdings + 16y at Novartis + McKinsey & Co) |
Person 2 | Gilman, David (ADC Therapeutics 202206– Chief Business + Strategy Officer before ClearView Healthcare Partners) | |
![]() |
Region | Epalinges VD |
Country | Switzerland | |
Street | 3B Route de la Corniche | |
City | 1066 Epalinges VD | |
Tel | +41-21-653-0200 | |
Address record changed: 2022-10-29 | ||
Basic data | Employees | D: 101 to 500 (2021-12-31) |
Currency | USD | |
Annual sales | 33,917,000 (revenue, total, consolidated (2021) 2021-12-31) | |
Profit | -230,026,000 (2021-12-31) | |
Cash | 466,544,000 (2021-12-31) | |
* Document for »About Section«: ADC Therapeutics S.A.. (6/13/22). "Press Release: ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer". Lausanne. | ||
Record changed: 2024-12-29 |
Advertisement

More documents for ADC Therapeutics (Group)
- [1] ADC Therapeutics S.A.. (5/6/24). "Press Release: ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants". Lausanne....
- [2] ADC Therapeutics S.A.. (7/20/23). "Press Release: ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of Zynlonta (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients". Lausanne....
- [3] ADC Therapeutics S.A.. (1/4/23). "Press Release: ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference". Lausanne....
- [4] ADC Therapeutics S.A.. (12/21/22). "Press Release: ADC Therapeutics and Sobi Announce European Commission Approval of Zynlonta (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma". Lausanne....
- [5] ADC Therapeutics S.A.. (12/19/22). "Press Release: ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer". Lausanne....
- [6] ADC Therapeutics S.A.. (11/1/22). "Press Release: ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer". Lausanne....
- [7] ADC Therapeutics S.A.. (9/6/22). "Press Release: ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference". Lausanne....
- [8] ADC Therapeutics S.A.. (8/15/22). "Press Release: ADC Therapeutics Announces $175 Million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes". Lausanne....
- [9] ADC Therapeutics S.A.. (7/8/22). "Press Release: ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Europe and Select International Territories". Lausanne....
- [10] ADC Therapeutics S.A.. (7/1/22). "Press Release: ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors". Lausanne....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top